# STARLITE 2 (NCT05239533)

> Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05239533
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Memorial Sloan Kettering Cancer Center
- Conditions: Clear Cell Renal Cell Carcinoma; Kidney Cancer; Advanced Renal Cell Carcinoma
- Interventions: 177Lu-labeled-girentuximab; Nivolumab; 89Zr-girentuximab PET/CT; 177Lu whole body (WB) planar and SPECT/CT scans
- Enrollment: 9
- Primary outcome: Maximal tolerated dose (MTD) of 177Lu-girentuximab
- Primary outcome: Overall Response Rate/ORR

## Indexed commentary on STARLITE 2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 8

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=starlite-2-nct05239533

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05239533", "email": "<work email>"}; the inbox owner confirms by the emailed link.